Simon Rule, MD from Plymouth University, Plymouth, UK provides an update on the three-year follow-up of the RAY (MCL 3001) trial (NCT01646021), presented at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. The RAY trial compares ibrutinib and temsirolimus in patients with previously treated mantle cell lymphoma, and at three years the data are promising. Prof. Rule explains that patients are experiencing durable responses, and toxicity has not worsened over time. While progression-free survival remains encouraging, overall-survival has decreased at the three-year mark.
This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.